Sugi Predict

Sugi Predict / Compounds / SCHEMBL722748

SCHEMBL722748

SCHEMBL722748

C[C@]12CCC(=O)C=C1CC[C@@H]1C2=CC[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 7/20 0.78
▸ CYP19A1 P11511 1/20 0.57
▸ HSD17B10 Q99714 7/20 0.57
▸ CYP2C19 P33261 4/20 0.57
▸ HIF1A Q16665 4/20 0.57
▸ SHBG P04278 3/20 0.57
▸ SERPINA6 P08185 3/20 0.57
▸ CYP3A4 P08684 3/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ LMNA P02545 2/20 0.57
▸ PMP22 Q01453 2/20 0.57
▸ TSHR P16473 2/20 0.57
▸ BLM P54132 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ KCNA1 Q09470 1/20 0.56
▸ SLC47A1 Q96FL8 1/20 0.56
▸ MAPK1 P28482 1/20 0.55
▸ PGR P06401 2/20 0.52
▸ NR3C2 P08235 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23974907 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL1274268 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL12704141 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL23974955 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL1275108 1.00 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
Anecortave Acetate SCHEMBL8472390 0.92 NR3C1 (0.93) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL9070362 0.92 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL18351260 0.92 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL9223381 0.92 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A
SCHEMBL9223554 0.92 NR3C1 (0.78) NR3C1CYP19A1HSD17B10CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4837861-B2 — — 2011-12-14 — — JP claimed
US-20080234245-A1 Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma ALCON, INC. (CH) 2008-09-25 — — US claimed
US-20080038316-A1 Conveniently implantable sustained release drug compositions RAMSCOR, INC. 2008-02-14 — — US claimed
US-20070197491-A1 Method for treating primary and secondary forms of glaucoma ALCON, INC. (CH) 2007-08-23 — — US claimed
EP-1781301-A2 ANGIOSTATIC AGENTS FOR CONTROLLING CHOROIDAL NEOVASCULARISATION AFTER OCULAR SURGERY OR TRAUMA Alcon Inc. (CH) 2007-05-09 — — EP claimed
EP-1755672-A2 METHODS AND ARTICLES FOR THE DELIVERY OF MEDICAMENTS TO THE EYE FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASES DIRECTCONTACT LLC (US) 2007-02-28 — — EP claimed
EP-1644057-A2 DRUG DELIVERY DEVICE AND SYRINGE FOR FILLING THE SAME (OSI) EYETECH, INC. (US) 2006-04-12 — — EP claimed
WO-2005110473-A2 METHODS AND ARTICLES FOR THE DELIVERY OF MEDICAMENTS TO THE EYE FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASES DIRECTCONTACT LLC (US) 2005-11-24 — — WO claimed
WO-2005102297-A2 ANGIOSTATIC AGENTS FOR CONTROLLING CHOROIDAL NEOVASCULARISATION AFTER OCULAR SURGERY OF TRAUMA ALCON, INC. (CH) 2005-11-03 — — WO claimed
US-20050239760-A1 Angiostatic agents and methods and compositions for controlling ocular hypertension ALCON, INC. 2005-10-27 — — US claimed
EP-0371617-B1 Use of angiostatic steroids in the manufacture of a medicament for controlling ocular hypertension ALCON LAB INC (US) 1994-06-08 — — EP claimed
EP-0350488-B1 1,2-DEHYDROGENATION OF STEROIDAL 21-ESTERS WITH A. SIMPLEX THE UPJOHN COMPANY (US) 1993-09-08 — — EP claimed
WO-1993010141-A2 ANGIOSTATIC STEROIDS ALCON LABORATORIES, INC. (US) 1993-05-27 — — WO claimed
EP-0489779-A4 OPHTHALMIC COMPOSITION — 1993-01-07 — — EP claimed
EP-0489779-A1 OPHTHALMIC COMPOSITION ALCON LABORATORIES, INC. (US) 1992-06-17 — — EP claimed
WO-1991019731-A1 STEROIDS WHICH INHIBIT ANGIOGENESIS THE UPJOHN COMPANY (US) 1991-12-26 — — WO claimed
WO-1991003245-A1 OPHTHALMIC COMPOSITION ALCON LABORATORIES, INC. (US) 1991-03-21 — — WO claimed
US-4876250-A Methods for controlling ocular hypertension with angiostatic steroids ALCON LABORATORIES, INC. (US) 1989-10-24 — — US claimed
EP-0186948-B1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 17ALPHA-HYDROXYPROGESTERONES AND CORTICOIDS FROM AN ENOL STEROID THE UPJOHN COMPANY (US) 1989-01-25 — — EP claimed
EP-0097328-B1 PROCESS FOR PREPARATION OF STEROIDS DAINIPPON INK AND CHEMICALS, INC. (JP) 1987-08-26 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239760-A1 Angiostatic agents and methods and compositions for controlling ocular hypertension VEGFA, SERPINA6, TIMP3 NR3C1 1783/4885CYP19A1 3772/4885HSD17B10 3816/4885
US-20080234245-A1 Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma VEGFA, SERPINA6, SERPINE1 NR3C1 3253/4885CYP19A1 3024/4885HSD17B10 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.